Mechanisms of Disease: fibroblasts - a new look at an old problem

被引:174
作者
Neilson, EG [1 ]
机构
[1] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA
来源
NATURE CLINICAL PRACTICE NEPHROLOGY | 2006年 / 2卷 / 02期
关键词
epithelial-mesenchymal transition; fibroblasts; fibrosis; FSP1; kidney;
D O I
10.1038/ncpneph0093
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Fibroblasts are one of the most important and episodically active cell types in the kidney. Under normal conditions, these cells provide a delicate collagenous matrix that partitions the interstitial spaces between nephrons, blood vessels and the renal capsule. Fibroblasts also remodel the interstitium as kidneys grow with age. This episodic activity of various fibroblast populations has a biological basis. Most fibroblasts are created locally through a process called epithelial - mesenchymal transition (EMT) and, once formed, they can proliferate in response to local mitogens. EMT is driven by an alteration in the balance of local cytokine concentrations that reverses the differentiation of selected epithelia along tubular nephrons. During persistent injury and inflammation, fibroblasts further increase their numbers and secrete excess interstitial collagens, and EMT is particularly aggressive in this setting. The mechanisms by which fibroblasts simultaneously destroy normal interstitial architecture and disable epithelial nephrons are more comprehensible today. Recent therapeutic clues for attenuating fibroblast formation during renal fibrogenesis also suggest an advantage in shifting local cytokine balance to favor mesenchymal - epithelial transition. This review examines these issues and identifies new targets for the treatment of one of the most difficult problems facing clinical nephrology.
引用
收藏
页码:101 / 108
页数:8
相关论文
共 70 条
[1]   Peripheral blood fibrocytes: Differentiation pathway and migration to wound sites [J].
Abe, R ;
Donnelly, SC ;
Peng, T ;
Bucala, R ;
Metz, CN .
JOURNAL OF IMMUNOLOGY, 2001, 166 (12) :7556-7562
[2]   Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β [J].
Abreu, JG ;
Ketpura, NI ;
Reversade, B ;
De Robertis, EM .
NATURE CELL BIOLOGY, 2002, 4 (08) :599-604
[3]   BIOSYNTHETIC AND PROLIFERATIVE CHARACTERISTICS OF TUBULOINTERSTITIAL FIBROBLASTS PROBED WITH PARACRINE CYTOKINES [J].
ALVAREZ, RJ ;
SUN, MJ ;
HAVERTY, TP ;
IOZZO, RV ;
MYERS, JC ;
NEILSON, EG .
KIDNEY INTERNATIONAL, 1992, 41 (01) :14-23
[4]   Chemokines and chemokine receptors are involved in the resolution or progression of renal disease [J].
Anders, HJ ;
Vielhauer, V ;
Schlöndorff, D .
KIDNEY INTERNATIONAL, 2003, 63 (02) :401-415
[5]   Extracellular regulation of BMP signaling in vertebrates: A cocktail of modulators [J].
Balemans, W ;
Van Hul, W .
DEVELOPMENTAL BIOLOGY, 2002, 250 (02) :231-250
[6]   Mesenchymal to epithelial conversion in rat metanephros is induced by LIF [J].
Barasch, J ;
Yang, J ;
Ware, CB ;
Taga, T ;
Yoshida, K ;
Erdjument-Bromage, H ;
Tempst, P ;
Parravicini, E ;
Malach, S ;
Aranoff, T ;
Oliver, JA .
CELL, 1999, 99 (04) :377-386
[7]   Induction of epithelial tubules by growth factor HGF depends on the STAT pathway [J].
Boccaccio, C ;
Andò, M ;
Tamagnone, L ;
Bardelli, A ;
Michieli, P ;
Battistini, C ;
Comoglio, PM .
NATURE, 1998, 391 (6664) :285-288
[8]   Regulation of PDGF and its receptors in fibrotic diseases [J].
Bonner, JC .
CYTOKINE & GROWTH FACTOR REVIEWS, 2004, 15 (04) :255-273
[9]   NATURAL INHIBITOR OF TRANSFORMING GROWTH-FACTOR-BETA PROTECTS AGAINST SCARRING IN EXPERIMENTAL KIDNEY-DISEASE [J].
BORDER, WA ;
NOBLE, NA ;
YAMAMOTO, T ;
HARPER, JR ;
YAMAGUCHI, Y ;
PIERSCHBACHER, MD ;
RUOSLAHTI, E .
NATURE, 1992, 360 (6402) :361-364
[10]   Remission of renal disease: recounting the challenge, acquiring the goal [J].
Brenner, BM .
JOURNAL OF CLINICAL INVESTIGATION, 2002, 110 (12) :1753-1758